InvestSMART

Aroa Biosurgery Limited (ASX:ARX)

ALERT: Price-sensitive ASX Announcement for ARX
Current share price for ARX : $0.630 -0.055 (-8.03%)+
Announcement
Release
25 Nov 2025 8:36AM
Price at Release
$0.685
Full Release
download
Summary
Aroa Biosurgery Limited reported strong financial results for the first half of FY26, with a 14% increase in total revenue to NZ$44.9 million and a significant turnaround in EBITDA from a NZ$1.5 million loss to a NZ$1.8 million profit. The company saw substantial growth in its Myriad product line, contributing to a product revenue of NZ$44.6 million. Operating cash flow improved significantly, and the company ended the period with a robust cash balance and no debt. Aroa Biosurgery reaffirmed its revenue and EBITDA guidance for the fiscal year and highlighted its strategic focus on strengthening its product portfolio through new clinical publications. This period marked the fourth consecutive quarter of positive operating cash flow, prompting the ASX to relieve the company from quarterly cash flow reporting obligations.
Key Points
  • Aroa Biosurgery Limited reported a total revenue of NZ$44.9 million for H1 FY26, a 14% increase from H1 FY25.
  • The company achieved a normalised EBITDA profit of NZ$1.8 million, compared to a loss of NZ$1.5 million in H1 FY25.
  • Product revenue was NZ$44.6 million, with the Myriad product revenue increasing by 33% year-on-year.
  • Research and development expenses decreased by 24% to NZ$4.1 million compared to H1 FY25.
  • Net cash inflow from operating activities was NZ$4.0 million, showing improvement from a NZ$4.9 million cash outflow in H1 FY25.
  • AROA ended H1 FY26 with a cash balance of NZ$23.4 million and remains debt-free.
  • The company reaffirmed its FY26 revenue guidance of NZ$92-100 million and expects a normalised EBITDA profit of NZ$5–8 million.
  • AROA has been relieved from its obligation to submit quarterly cash flow reports to the ASX due to consistent positive cash flow.
  • Future expectations include new clinical publications to validate AROA ECM’s efficacy and improve commercial uptake.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.